Novavax’s COVID-19 vaccine headed into the clinic; data due in July

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Novavax could have preliminary data as soon as July from a planned first-in-human trial of its COVID-19 vaccine, the company said Wednesday.

Next month, Novavax Inc. (NASDAQ:NVAX) intends to start the Phase I trial of NVX-CoV2373, with about 130 healthy adult subjects receiving the vaccine or placebo. Novavax said the trial is starting weeks ahead of schedule; early safety and immunogenicity results are due two months later.

Novavax’s entrant would follow a handful of other vaccines into the clinic. NIH began a Phase I study last month of MRNA-1273, the vaccine candidate developed by Moderna Inc. (NASDAQ:MRNA), while Chinese regulators last month cleared CanSino Biologics Inc. (HKSE:6185) to begin a Phase I study of its vaccine, Ad5-nCoV. And on Monday, Inovio Pharmaceuticals Inc. (NASDAQ:INO) said it had begun a Phase I study of INO-4800.

Novavax would follow the Phase I trial with a Phase II study. NVX-CoV2373 uses the company’s recombinant nanoparticle technology and Matrix-M adjuvant.

The Coalition for Epidemic Preparedness Innovations has funded Novavax with $4 million for its COVID-19 vaccine development. The company said Wednesday it is discussing additional funding with CEPI.

Novavax climbed $2.28 (15%) to $17.18 Wednesday.

Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus.

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE